<?xml version="1.0" encoding="UTF-8"?>
<p>Among individuals developing bnAbs, a small fraction of patients (1%) called elite neutralizers, develop very broad and highly potent bnAbs able to neutralize isolates of various subtypes in vitro [
 <xref rid="B27-vaccines-07-00074" ref-type="bibr">27</xref>,
 <xref rid="B36-vaccines-07-00074" ref-type="bibr">36</xref>]. Since 2009, thanks to the development of single-cell-based antibody cloning techniques, a large number of bnAbs with outstanding breadth and potency have been generated from these elite neutralizers [
 <xref rid="B37-vaccines-07-00074" ref-type="bibr">37</xref>,
 <xref rid="B38-vaccines-07-00074" ref-type="bibr">38</xref>,
 <xref rid="B39-vaccines-07-00074" ref-type="bibr">39</xref>,
 <xref rid="B40-vaccines-07-00074" ref-type="bibr">40</xref>]. Passive transfer studies with bnAbs in nonhuman primates have demonstrated effective protection against simian/human immunodeficiency virus (SHIV) [
 <xref rid="B41-vaccines-07-00074" ref-type="bibr">41</xref>,
 <xref rid="B42-vaccines-07-00074" ref-type="bibr">42</xref>,
 <xref rid="B43-vaccines-07-00074" ref-type="bibr">43</xref>]. The bnAbsâ€™ functionality lies in their ability to bind and clear both cell-free viruses and infected cells [
 <xref rid="B44-vaccines-07-00074" ref-type="bibr">44</xref>,
 <xref rid="B45-vaccines-07-00074" ref-type="bibr">45</xref>]. 
</p>
